It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...

It certainly was a big week — with companies having to raise more than $100 million to make the list. Biotech- and healthcare-related startups led the way — as those companies dominate the list, ...

Verdiva launched with $411 million. Indian drugmaker Anthem Biosciences filed for an IPO worth $397 million. Tenvie Therapeutics emerged with $200 million. Maze Therapeutics files for $115 million ...

Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report) and keeping the price target at $8.00. Discover outperforming stocks and invest ...

Tenvie Therapeutics Inc. is getting a set of small-molecule drugs — specifically, ones aimed at tamping down inflammation, rescuing metabolic dysfunction and restoring lysosomal function ...

About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in the Denali team with a proposal to spin out the small-molecule drugs with ...

The company is advancing a pipeline of therapeutics, including programs acquired from Denali Therapeutics Inc., focused on treating neurological, cardiometabolic and ophthalmic diseases.